$BCLI
BRAINSTORM CELL THERAPEUTICS INC.

2022 Q4 Form 10-Q Financial Statement

#000141057822003271 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.464M $3.065M $1.659M
YoY Change -2.8% 84.75% -36.68%
% of Gross Profit
Research & Development $2.451M $3.776M $3.618M
YoY Change -33.34% 4.37% 93.79%
% of Gross Profit
Depreciation & Amortization $70.00K $70.00K $67.00K
YoY Change 0.0% 4.48% 19.64%
% of Gross Profit
Operating Expenses $4.915M $3.776M $3.618M
YoY Change -20.88% 4.37% 93.79%
Operating Profit -$6.841M -$5.277M
YoY Change 29.64% 17.66%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$103.0K -$17.00K -$59.00K
YoY Change -568.18% -71.19%
Pretax Income -$5.018M -$6.858M -$5.336M
YoY Change -18.93% 28.52% 18.84%
Income Tax
% Of Pretax Income
Net Earnings -$5.018M -$6.858M -$5.336M
YoY Change -18.93% 28.52% 18.89%
Net Earnings / Revenue
Basic Earnings Per Share -$0.19 -$0.15
Diluted Earnings Per Share -$0.14 -$0.19 -$147.0K
COMMON SHARES
Basic Shares Outstanding 36.54M 36.49M 36.30M
Diluted Shares Outstanding 36.49M 36.30M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.983M $7.393M $27.81M
YoY Change -86.5% -73.42% -3.47%
Cash & Equivalents $772.0K $4.144M $25.70M
Short-Term Investments $2.211M $3.249M $2.114M
Other Short-Term Assets $32.00K $51.00K $50.00K
YoY Change -97.09% 2.0% -16.67%
Inventory
Prepaid Expenses
Receivables $91.00K $58.00K $85.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.106M $7.502M $27.94M
YoY Change -86.66% -73.15% -7.89%
LONG-TERM ASSETS
Property, Plant & Equipment $933.0K $1.003M $1.224M
YoY Change -21.53% -18.06% 28.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.345M $5.752M $6.594M
YoY Change -10.87% -12.77% 180.12%
Total Long-Term Assets $5.345M $5.752M $6.594M
YoY Change -10.87% -12.77% 180.12%
TOTAL ASSETS
Total Short-Term Assets $3.106M $7.502M $27.94M
Total Long-Term Assets $5.345M $5.752M $6.594M
Total Assets $8.451M $13.25M $34.54M
YoY Change -71.13% -61.62% 5.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.224M $6.395M $2.739M
YoY Change 68.22% 133.48% -16.57%
Accrued Expenses $84.00K $58.00K $387.0K
YoY Change 1.2% -85.01% -57.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.800M $8.948M $5.846M
YoY Change 39.31% 53.06% -9.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.666M $2.918M $3.766M
YoY Change -26.31% -22.52% 1245.0%
Total Long-Term Liabilities $2.666M $2.918M $3.766M
YoY Change -26.31% -22.52% 1226.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.800M $8.948M $5.846M
Total Long-Term Liabilities $2.666M $2.918M $3.766M
Total Liabilities $11.47M $11.87M $9.612M
YoY Change 15.41% 23.45% 43.18%
SHAREHOLDERS EQUITY
Retained Earnings -$198.0M -$193.0M -$167.0M
YoY Change 14.09% 15.57% 21.66%
Common Stock $194.9M $194.3M $192.4M
YoY Change 0.99% 0.99% 17.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.015M $1.388M $24.93M
YoY Change
Total Liabilities & Shareholders Equity $8.451M $13.25M $34.54M
YoY Change -71.13% -61.62% 5.65%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$5.018M -$6.858M -$5.336M
YoY Change -18.93% 28.52% 18.89%
Depreciation, Depletion And Amortization $70.00K $70.00K $67.00K
YoY Change 0.0% 4.48% 19.64%
Cash From Operating Activities -$4.648M -$4.850M -$6.460M
YoY Change -15.61% -24.92% -6.7%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $1.000K $237.0K
YoY Change -100.0% -99.58% 169.32%
Acquisitions
YoY Change
Other Investing Activities $1.038M -$10.00K $1.933M
YoY Change -182.25% -100.52%
Cash From Investing Activities $1.038M -$11.00K $1.696M
YoY Change -180.03% -100.65% -2072.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 238.0K 0.000 -106.0K
YoY Change -800.0% -100.0% -100.54%
NET CHANGE
Cash From Operating Activities -4.648M -4.850M -6.460M
Cash From Investing Activities 1.038M -11.00K 1.696M
Cash From Financing Activities 238.0K 0.000 -106.0K
Net Change In Cash -3.372M -4.861M -4.870M
YoY Change -50.69% -0.18% -138.6%
FREE CASH FLOW
Cash From Operating Activities -$4.648M -$4.850M -$6.460M
Capital Expenditures $0.00 $1.000K $237.0K
Free Cash Flow -$4.648M -$4.851M -$6.697M
YoY Change -15.07% -27.56% -4.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36472372
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36140130
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36493432
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36304878
dei Entity Central Index Key
EntityCentralIndexKey
0001137883
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
bcli Validity Of Royalty Payment Not Covered By Valid Claim Or Orphan Drug Status
ValidityOfRoyaltyPaymentNotCoveredByValidClaimOrOrphanDrugStatus
P15Y
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36401413
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36541779
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36641
dei Entity Registrant Name
EntityRegistrantName
BRAINSTORM CELL THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-7273918
dei Entity Address Address Line1
EntityAddressAddressLine1
1325 Avenue of Americas, 28th Floor
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address City Or Town
EntityAddressCityOrTown
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10019
dei City Area Code
CityAreaCode
201
dei Local Phone Number
LocalPhoneNumber
488-0460
dei Security12b Title
Security12bTitle
Common Stock, $0.00005 par value
dei Trading Symbol
TradingSymbol
BCLI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36541779
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4144000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18856000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
3249000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
3238000
CY2022Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
58000
CY2021Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
86000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
51000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1100000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
7502000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
23280000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
23000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
27000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4726000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4781000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1003000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1189000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5752000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5997000
CY2022Q3 us-gaap Assets
Assets
13254000
CY2021Q4 us-gaap Assets
Assets
29277000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6395000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3700000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
83000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1460000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1461000
CY2022Q3 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1035000
CY2021Q4 bcli Other Accounts Payable Current
OtherAccountsPayableCurrent
1073000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8948000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6317000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2918000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3618000
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2918000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3618000
CY2022Q3 us-gaap Liabilities
Liabilities
11866000
CY2021Q4 us-gaap Liabilities
Liabilities
9935000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
12000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00005
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6269000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
30172000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36541779
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36401413
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
194295000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
192990000
CY2022Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
116000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192803000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173544000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1388000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13254000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29277000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11505000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11558000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3776000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3618000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8402000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6769000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3065000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1659000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19907000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18327000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6841000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5277000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-648000
bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
-60000
CY2022Q3 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
17000
CY2021Q3 bcli Financial Expenses Income Net
FinancialExpensesIncomeNet
59000
us-gaap Net Income Loss
NetIncomeLoss
-19259000
us-gaap Net Income Loss
NetIncomeLoss
-18267000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6858000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5336000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36472372
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36140130
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36493432
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36304878
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35464000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
290000
CY2021Q1 bcli Issuance Of Shares At Market
IssuanceOfSharesAtMarket
7104000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6662000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
36201000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
240000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
196000
CY2021Q3 bcli Issuance Costs Related To At Market Offering
IssuanceCostsRelatedToAtMarketOffering
106000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-1243000
CY2022Q3 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-457000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5336000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
24926000
CY2021Q3 bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-516000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19342000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
505000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5360000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
14487000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
405000
CY2022Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
395000
CY2021Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
196000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7041000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
7851000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
395000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6858000
bcli Increase Decrease In Operating Lease Expense Income
IncreaseDecreaseInOperatingLeaseExpenseIncome
-646000
bcli Increase Decrease In Operating Lease Expense Income
IncreaseDecreaseInOperatingLeaseExpenseIncome
-182000
CY2022Q3 bcli Increase Decrease In Operating Lease Expense Income
IncreaseDecreaseInOperatingLeaseExpenseIncome
-34000
CY2021Q3 bcli Increase Decrease In Operating Lease Expense Income
IncreaseDecreaseInOperatingLeaseExpenseIncome
8000
bcli Increase Decrease In Accounts Receivable And Prepaid Expenses
IncreaseDecreaseInAccountsReceivableAndPrepaidExpenses
-1081000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1388000
us-gaap Profit Loss
ProfitLoss
-19259000
us-gaap Profit Loss
ProfitLoss
-18267000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-6858000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-5336000
us-gaap Depreciation
Depreciation
215000
us-gaap Depreciation
Depreciation
190000
CY2022Q3 us-gaap Depreciation
Depreciation
70000
CY2021Q3 us-gaap Depreciation
Depreciation
67000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1305000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
726000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2695000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2678000
CY2022Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1103000
CY2021Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-261000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-63000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1789000
CY2022Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
17000
CY2021Q3 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1650000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14672000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20757000
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4850000
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6460000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
295000
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1000
CY2021Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
237000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
11000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-1915000
CY2022Q3 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
10000
CY2021Q3 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-1933000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1620000
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11000
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1696000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
bcli Proceeds From At Market
ProceedsFromAtMarket
6998000
CY2021Q3 bcli Proceeds From At Market
ProceedsFromAtMarket
-106000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7003000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25695000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4144000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25695000
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-106000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14712000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12134000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4861000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4870000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18856000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37829000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9005000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30565000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4144000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 58.3pt;"><b style="font-size:10pt;font-weight:bold;">D.     </b><b style="font-weight:bold;"> </b><b style="font-size:10pt;font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 82.8pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</p>
bcli Percentage Of Royalty Payment If Licensed Product Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductCoveredByValidClaimOrOrphanDrugStatus
0.05
bcli Percentage Of Royalty Payment If Licensed Product Not Covered By Valid Claim Or Orphan Drug Status
PercentageOfRoyaltyPaymentIfLicensedProductNotCoveredByValidClaimOrOrphanDrugStatus
0.03
bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P1Y3M
CY2021 bcli Maturity Of Interest Bearing Bank Deposits
MaturityOfInterestBearingBankDeposits
P1Y3M
CY2022Q3 us-gaap Prepaid Rent
PrepaidRent
36000
CY2021Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
1086000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4726000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4378000
us-gaap Operating Lease Payments
OperatingLeasePayments
2045000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M25D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0675
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
351000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1037000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1378000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1147000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
193000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4106000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
272000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4378000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000000.0
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1250000
CY2020Q1 us-gaap Share Price
SharePrice
8.00
CY2020Q1 bcli Warrant Term
WarrantTerm
P3Y
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
250000
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
151000000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
272596
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.49
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y2M23D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
95366
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
100641
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
5.84
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
267321
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.70
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y4M9D
us-gaap Share Based Compensation
ShareBasedCompensation
1305000
us-gaap Share Based Compensation
ShareBasedCompensation
726000
CY2022Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
11705000
CY2021Q3 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
12222000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11505000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11558000

Files In Submission

Name View Source Status
bcli-20220930_cal.xml Edgar Link unprocessable
0001410578-22-003271-index-headers.html Edgar Link pending
0001410578-22-003271-index.html Edgar Link pending
0001410578-22-003271.txt Edgar Link pending
0001410578-22-003271-xbrl.zip Edgar Link pending
bcli-20220930.xsd Edgar Link pending
bcli-20220930x10q.htm Edgar Link pending
bcli-20220930xex31d1.htm Edgar Link pending
bcli-20220930xex31d2.htm Edgar Link pending
bcli-20220930xex32d1.htm Edgar Link pending
bcli-20220930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
bcli-20220930_lab.xml Edgar Link unprocessable
bcli-20220930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bcli-20220930_pre.xml Edgar Link unprocessable
bcli-20220930x10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending